Regeneron (REGN) announced three-year data for EYLEA HD Injection 8 mg from an extension study of the Phase 3 PHOTON trial in patients with diabetic macular edema, or DME. At three years ...

SAN FRANCISCO — Regeneron said Monday that it collected $1.5 billion in revenues from its blockbuster eye degeneration drug Eylea in the fourth quarter — a substantial sum for many companies ...

At three years of EYLEA HD treatment, the vast majority of patients maintained visual and anatomic improvements while achieving extended dosing regimens, including those of just twice a year ...

High-dose Eylea, or aflibercept 8 mg, is being jointly developed by Regeneron and Bayer AG. Regeneron shares were down 1.3% Tuesday before being halted in advance of the news. Back To Top ...

Three years ago, the FDA cleared Regeneron’s Eylea for use against diabetic retinopathy, a condition that strikes more than a third of diabetics and can cause blindness. Now the company is worki ...

April 29 (Reuters) - Regeneron's (REGN.O), opens new tab first-quarter results missed Wall Street estimates on Tuesday due to stiff competition for its blockbuster drug Eylea, further stoking ...

Please provide your email address to receive an email when new articles are posted on . The Committee for Medicinal Products for Human Use of the European Medicines Agency granted a positive ...

If approved, EYLEA HD would be the first and only treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period, reducing the number of injections by half ...